top of page


Sculptra® Aesthetic works subtly and gradually over time for a more youthful-looking appearance. 
80% of users who received Sulptra were still satisfied with their treatment results 25 months after their last injection.

Sculptra is a proprietary formulation of poly-L-lactic acid (PLLA) that is an FDA-approved dermal filler manufactured by Galderma Laboratories. PLLA was approved by the FDA on August 3, 2004, for the treatment of facial fat loss (also called facial lipoatrophy). According to documents from the US Food and Drug Administration, the FDA initially approved the drug on the basis of small studies conducted on HIV patients, specifically “for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV).

What is Lipoatrohpy?
Facial lipoatrophy is a condition in which people lose fat in their faces, especially in their cheeks and around their eyes and temples. People with HIV who take anti-HIV drugs may develop lipoatrophy. Sculptra was subsequently approved by the FDA for use with non-HIV patients with wrinkles, despite substantial complications reported to the FDA. PLLA is injected into the skin in areas where fat has been lost. It causes the skin to thicken via collagen neo-synthesis, improves appearance of folds and sunken areas, and hides the fat loss. For most people who participated in PLLA clinical studies, the effects of treatment lasted for two years. PLLA is primarily used by physicians as a volume filler for lipoatrophy of cheeks in thin fit women or men who have lost facial fat. It, along with other formulations like Dysport and Restylane, has been called a "liquid facelift" because adding volume to the malar and cheek areas lifts sagging areas of the atrophic face.
Sculptra Side Effects
Side effects of Sculptra injections included the delayed appearance of small bumps under the skin in the treated area. Other side effects included bleeding, tenderness or discomfort, redness, bruising, or swelling


bottom of page